Better Together? Costs of First-line Chemoimmunotherapy for Advanced Non–Small Cell Lung CancerMay 18th 2023
Compared with first-line immunotherapy or chemotherapy alone, combination chemoimmunotherapy for advanced/metastatic non–small cell lung cancer has significantly higher antineoplastic drug and associated medical costs.
Reflex Testing and Reimbursements for Oncology TreatmentMarch 4th 2022
Payer perspective regarding decisions for covering the costs of molecular assays in oncology and reimbursing oncologists for treatments provided to patients while navigating long turnaround times associated with reflex testing.